Eydelman Mikhail 4
4 · Vaxcyte, Inc. · Filed Mar 7, 2025
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Eydelman Mikhail
SVP, GEN COUNSEL & CORP SEC
Transactions
- Sale
Common Stock
2025-03-05$70.39/sh−2,621$184,487→ 43,999 total - Exercise/Conversion
Stock Option (right to buy)
2025-03-05−5,000→ 144,497 totalExercise: $21.41Exp: 2032-05-08→ Common Stock (5,000 underlying) - Sale
Common Stock
2025-03-05$71.07/sh−2,267$161,107→ 41,732 total - Exercise/Conversion
Common Stock
2025-03-05$21.41/sh+5,000$107,050→ 46,620 total - Sale
Common Stock
2025-03-05$72.37/sh−112$8,105→ 41,620 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.